FierceBiotech's most popular stories of 2008

With 2008 behind us, we'd like to take a look back at the stories and special reports our readers found most interesting over the past year. Unlike the 2007 list, which was dominated by Pfizer news, 2008's top stories covered a mixed bag of topics, ranging from breakthroughs at ACT and Follica to the ongoing financial problems plaguing the biotech industry.

As for our most popular special reports, our annual Fierce 15 was the most-read feature this year. Reports on 2007 venture capital deals and FDA approvals also topped the charts, and our popular piece on expert advice for small biotechs rounded out this year's top five.

Finally, the profile on emerging drug developer Tengion captured the most reader interest. Follica also made it to the number two spot on the list.

Top 10 stories of 2008

  • ACT says it has found key to limitless blood supply
  • Follica sees bushy prospects in baldness therapy
  • Roche to move out of Palo Alto
  • FDA announces several approvals
  • Novartis discovery chief departs in management shakeup
  • Lilly readies Phase III Alzheimer's trial
  • The 2008 Election: What does it mean for drugmakers?
  • What's next for Genentech employees?
  • Pfizer R&D staff braces for layoffs
  • More biotech bankruptcies on the horizon

Top 5 features of 2008

  • 2008 Fierce 15
  • Top 20 VC deals of 2007
  • 2007 FDA approvals
  • Top Five Regions Targeting Biotech Companies - 2008
  • Top 10 mistakes biotechs make (and how to avoid them)

Top 5 profiles of 2008

  • Tengion
  • Follica
  • Sonexa Therapeutics
  • Aileron Therapeutics
  • CombinatoRx

FierceBiotech's most popular stories of 2008

Suggested Articles

Inclisiran achieved a placebo-adjusted drop in LDL cholesterol of 58%, although it failed to drive positive changes in cardiovascular outcomes.

Amgen has found no evidence that heart failure drug omecamtiv mecarbil hampers diastolic function in a post hoc analysis of phase 2 data.

We tend to think of heart disease and heart disorders to be, in the main, things that affect men more than women, but this is not true.